A number of investment brokers have recently updated their price targets on shares of Bellerophon Therapeutics, Inc. (BLPH). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/22/2016 – Bellerophon Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 9 price target on the stock.

09/30/2015 – Bellerophon Therapeutics, Inc. had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 11 price target on the stock.

08/24/2015 – Bellerophon Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 10 price target on the stock.

05/01/2015 – Bellerophon Therapeutics, Inc. had its “hold” rating reiterated by analysts at Zacks.

04/07/2015 – Bellerophon Therapeutics, Inc. had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 23 price target on the stock.

The share price of Bellerophon Therapeutics, Inc. (BLPH) was down -4.50% during the last day of trading, with a day high of 1.84. 17356 shares were traded during the last session.

The stock’s 50 day moving average is 2.26 and its 200 day moving average is 2.63. The stock’s market capitalization is 22.64M. Bellerophon Therapeutics, Inc. has a 52-week low of 1.72 and a 52-week high of 9.72.

View other investors thoughts on Bellerophon Therapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.